Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SR-878 in Healthy Volunteers
NCT06607484Phase 1Terminated
- Sponsor
- SciRhom GmbH
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) comparing SR-878 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2024; status: terminated.
02
Drugs
SR-878
03
Conditions
autoimmune diseasesrheumatoid arthritis (RA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06607484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607484.